Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD1 | O60671 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | LTA | P01374 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | SENP2 | Q9HC62 | 5/20 | 0.37 |
| ▸ | SENP1 | Q9P0U3 | 5/20 | 0.37 |
| ▸ | SENP3 | Q9H4L4 | 4/20 | 0.37 |
| ▸ | SUMO2 | P61956 | 3/20 | 0.37 |
| ▸ | SUMO1 | P63165 | 3/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978315 | 1.00 | RAD1 (0.51) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL344713 | 1.00 | RAD1 (0.51) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL2834140 | 0.92 | RAD1 (0.48) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL156112 | 0.90 | RAD1 (0.47) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL2834143 | 0.86 | RAD1 (0.51) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL156114 | 0.85 | RAD1 (0.50) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL6114392 | 0.84 | ALDH1A1 (0.50) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL10622332 | 0.79 | APEX1 (0.47) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL1508924 | 0.77 | ALDH1A1 (0.62) | RAD1P2RY6ALDH1A1POLBTDP1 | |
| SCHEMBL29655855 | 0.77 | ALDH1A1 (0.62) | RAD1P2RY6ALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334472-A1 | COMPOSITIONS AND METHODS FOR DETECTING HEPATITIS DELTA VIRUS BY A DUAL-TARGET ASSAY | F. Hoffmann-La Roche AG (CH) | 2024-03-13 | — | — | EP | disclosed |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2022233930-A1 | COMPOSITIONS AND METHODS FOR DETECTING HEPATITIS DELTA VIRUS BY A DUAL-TARGET ASSAY | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-10 | — | — | WO | disclosed |
| EP-4085156-A1 | QUANTITATIVE PCR SCREENING OF INDUCIBLE PROPHAGE FROM BACTERIAL ISOLATES | F. Hoffmann-La Roche AG (CH) | 2022-11-09 | — | — | EP | disclosed |
| EP-4004240-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF EPSTEIN BARR VIRUS (EBV) | F. Hoffmann-La Roche AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-03-12 | — | — | US | disclosed |
| US-7160729-B2 | Method for detecting diseases that are associated with defects of cystic fibrosis transmembrane conductance regulator (CFTR) protein | SCHILLERS HERMANN | 2007-01-09 | — | — | US | disclosed |
| US-20050221273-A1 | Method for detecting diseases that are associated with defects of cystic fibrosis transmembrane conductance regulator (cftr)protein | SCHILLERS HERMANN | 2005-10-06 | — | — | US | disclosed |
| EP-0439585-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. | EPIPHARM ALLERGIE SERVICE (AT) | 1991-08-07 | — | — | EP | disclosed |
| WO-1991002768-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | TYMP, DUT, NT5C3B | RAD1 407/4885P2RY6 490/4885ALDH1A1 3387/4885 |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | TYMP, DUT, NT5C3B | RAD1 407/4885P2RY6 490/4885ALDH1A1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.